Bristol Myers Squibb wins FDA approval for Opdivo plus AVD in stage III-IV classical Hodgkin lymphoma

Bristol-Myers Squibb Company -2.45%

Bristol-Myers Squibb Company

BMY

59.60

-2.45%

  • Opdivo (nivolumab) received FDA approval in combination with doxorubicin, vinblastine and dacarbazine for adults and pediatric patients aged 12+ with previously untreated Stage III or IV classical Hodgkin lymphoma.
  • The European Commission approved Opdivo with brentuximab vedotin for patients aged 5+ up to 30 with relapsed or refractory classical Hodgkin lymphoma after one prior line of therapy.
  • A submission based on the Phase 3 SWOG 1826 study is under review by the EMA.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bristol-Myers Squibb Company published the original content used to generate this news brief via Business Wire (Ref. ID: 20260320986254) on March 20, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.